A clinical trial to compare a 3D‐printed bolus with a conventional bolus with the aim of reducing cardiopulmonary exposure in postmastectomy patients with volumetric modulated arc therapy

Abstract

Abstract Background We compared the dosimetry, application, and acute toxicity of a 3D‐printed and a conventional bolus for postmastectomy radiotherapy (PMRT) with volumetric modulated arc therapy (VMAT). Materials and Methods Eligible patients ( n = 75) with PMRT breast cancer were randomly selected to receive VMAT with a conventional bolus or a 3D‐printed bolus. The primary endpoint was a 10% decrease in the mean heart dose to left‐sided breast cancer patients. The secondary endpoint was a 5% decrease in the mean ipsilateral lung dose to all patients. A comparative analysis was carried out of the dosimetry, normal tissue complication probability (NTCP), acute skin toxicity, and radiation pneumonitis. Results Compared to a conventional bolus, the mean heart dose in left‐sided breast cancer was reduced by an average of 0.8 Gy (5.5 ± 1.3 Gy vs. 4.7 ± 0.8 Gy, p = 0.035) and the mean dose to the ipsilateral lung was also reduced by an average of 0.8 Gy (12.4 ± 1.0 Gy vs. 11.6 ± 0.8 Gy, p < 0.001). The values for V 50Gy of the PTV of the chest wall for the 3D‐printed and conventional boluses were 95.4 ± 0.6% and 94.8 ± 0.8% ( p = 0.026) and the values for the CI of the entire PTV were 0.83 ± 0.02 and 0.80 ± 0.03 ( p < 0.001), respectively. The NTCP for the 3D‐printed bolus was also reduced to an average of 0.14% (0.32 ± 0.19% vs. 0.18 ± 0.11%, p = 0.017) for the heart and 0.45% (3.70 ± 0.67% vs. 3.25 ± 0.18%, p < 0.001) for the ipsilateral lung. Grade 2 and Grade 1 radiation pneumonitis were 0.0% versus 7.5% and 14.3% versus 20.0%, respectively ( p = 0.184). Conclusions The 3D‐printed bolus may reduce cardiopulmonary exposure in postmastectomy patients with volumetric modulated arc therapy.